Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 9/20 | 0.57 |
| ▸ | MAOA | P21397 | 3/20 | 0.57 |
| ▸ | RXRA | P19793 | 1/20 | 0.55 |
| ▸ | RXRB | P28702 | 1/20 | 0.55 |
| ▸ | RXRG | P48443 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5089265 | 0.88 | MAOB (0.57) | ALOX5MAOBMAOAFFAR1PKM | |
| SCHEMBL5090959 | 0.86 | MAOB (0.55) | MAOBFFAR1PKM | |
| SCHEMBL5087369 | 0.86 | MAOB (0.57) | MAOBMAOAFFAR1 | |
| SCHEMBL5087384 | 0.85 | MAOB (0.53) | MAOBMAOAFFAR1 | |
| SCHEMBL5090322 | 0.85 | L3MBTL1 (0.56) | ALOX5MAOB | |
| SCHEMBL5095882 | 0.84 | FFAR1 (0.54) | MAOBMAOAFFAR1GRM5PKM | |
| SCHEMBL5087189 | 0.83 | MAOB (0.60) | MAOBFFAR1 | |
| SCHEMBL5090796 | 0.82 | MAOB (0.56) | ALOX5MAOBMAOAFFAR1PKM | |
| SCHEMBL5090794 | 0.82 | MAOB (0.49) | ALOX5MAOB | |
| SCHEMBL5096534 | 0.81 | MAOB (0.48) | ALOX5MAOBMAOAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188561-A1 | N-[2-AMINO-4-(PHENYLMETHOXY)PHENYL] AMIDES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS | JPMORGAN CHASE BANK, N.A. | 2008-08-07 | — | — | US | claimed |
| US-8722929-B2 | N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2014-05-13 | — | — | US | disclosed |
| US-20080188561-A1 | N-[2-AMINO-4-(PHENYLMETHOXY)PHENYL] AMIDES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS | JPMORGAN CHASE BANK, N.A. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188561-A1 | N-[2-AMINO-4-(PHENYLMETHOXY)PHENYL] AMIDES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS | KCNB2, KCNJ2, KCNA2 | ALOX5 1931/4885MAOB 808/4885MAOA 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.